Overview

Amisulpride Treatment for BPSD in AD Patients

Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
Currently, olanzapine is the most widely used and studied drug for the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease, but there are significant side effects. Amisulpride is a new antipsychotic that not only controls mental symptoms but also improves cognitive function. Therefore, the aim of this study was to evaluate the effectiveness and tolerability of both amisulpride and Olanzapine for treating the behavioral and psychological symptoms of dementia in patients with dementia of the Alzheimer type.
Phase:
N/A
Details
Lead Sponsor:
Tianjin Anding Hospital
Treatments:
Amisulpride
Olanzapine